141 related articles for article (PubMed ID: 12930142)
1. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
[TBL] [Abstract][Full Text] [Related]
2. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors.
Lepper ER; Ng SS; Gütschow M; Weiss M; Hauschildt S; Hecker TK; Luzzio FA; Eger K; Figg WD
J Med Chem; 2004 Apr; 47(9):2219-27. PubMed ID: 15084120
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
Ng SS; Gütschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD
Cancer Res; 2003 Jun; 63(12):3189-94. PubMed ID: 12810647
[TBL] [Abstract][Full Text] [Related]
4. Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide.
Helm FC; Frankus E; Friderichs E; Graudums I; Flohé L
Arzneimittelforschung; 1981; 31(6):941-9. PubMed ID: 7196239
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitors derived from thalidomide.
Noguchi T; Fujimoto H; Sano H; Miyajima A; Miyachi H; Hashimoto Y
Bioorg Med Chem Lett; 2005 Dec; 15(24):5509-13. PubMed ID: 16183272
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and TNF expression inhibitory properties of new thalidomide analogues derived via Heck cross coupling.
Stewart SG; Spagnolo D; Polomska ME; Sin M; Karimi M; Abraham LJ
Bioorg Med Chem Lett; 2007 Nov; 17(21):5819-24. PubMed ID: 17851074
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain.
Ryu JK; McLarnon JG
Neurobiol Dis; 2008 Feb; 29(2):254-66. PubMed ID: 17964176
[TBL] [Abstract][Full Text] [Related]
8. Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application.
Contino-Pépin C; Parat A; Périno S; Lenoir C; Vidal M; Galons H; Karlik S; Pucci B
Bioorg Med Chem Lett; 2009 Feb; 19(3):878-81. PubMed ID: 19103485
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats.
Liu KH; Liao LM; Ro LS; Wu YL; Yeh TS
Surgery; 2008 Mar; 143(3):375-83. PubMed ID: 18291259
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
Du GJ; Lin HH; Xu QT; Wang MW
Vascul Pharmacol; 2005 Aug; 43(2):112-9. PubMed ID: 15982930
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs.
Peach ML; Beedie SL; Chau CH; Collins MK; Markolovic S; Luo W; Tweedie D; Steinebach C; Greig NH; Gütschow M; Vargesson N; Nicklaus MC; Figg WD
Molecules; 2020 Dec; 25(23):. PubMed ID: 33276504
[TBL] [Abstract][Full Text] [Related]
12. Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-alpha production.
Fernández Braña M; Acero N; Añorbe L; Muñoz Mingarro D; Llinares F; Domínguez G
Eur J Med Chem; 2009 Sep; 44(9):3533-42. PubMed ID: 19394719
[TBL] [Abstract][Full Text] [Related]
13. Determination of the thalidomide analogues 2-(2,6-dioxopiperidine-3-yl)phthalimidine (EM 12), 2-(2,6-dioxopiperidine-4-yl)phthalimidine (EM 16) and their metabolites in biological samples.
Winckler K; Klinkmüller KD; Schmahl HJ
J Chromatogr; 1989 Mar; 488(2):417-25. PubMed ID: 2501333
[TBL] [Abstract][Full Text] [Related]
14. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.
Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI
J Med Chem; 1996 Aug; 39(17):3238-40. PubMed ID: 8765505
[No Abstract] [Full Text] [Related]
15. 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.
Price DK; Ando Y; Kruger EA; Weiss M; Figg WD
Ther Drug Monit; 2002 Feb; 24(1):104-10. PubMed ID: 11805730
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
17. [Synthesis of 1,3-dihydro-1,3-dioxo-2H-isoindole derivatives].
Yang Y; Xiang D; Guo J; Zheng YS; Ye B; Yang JL; Cheng L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):645-7. PubMed ID: 18798515
[TBL] [Abstract][Full Text] [Related]
18. Solid-phase synthesis of thalidomide and its analogues.
Xiao Z; Schaefer K; Firestine S; Li PK
J Comb Chem; 2002; 4(2):149-53. PubMed ID: 11886289
[TBL] [Abstract][Full Text] [Related]
19. LASSBio-468: a new achiral thalidomide analogue which modulates TNF-alpha and NO production and inhibits endotoxic shock and arthritis in an animal model.
Alexandre-Moreira MS; Takiya CM; de Arruda LB; Pascarelli B; Gomes RN; Castro Faria Neto HC; Lima LM; Barreiro EJ
Int Immunopharmacol; 2005 Mar; 5(3):485-94. PubMed ID: 15683845
[TBL] [Abstract][Full Text] [Related]
20. [Search for new anti-angiogenic agents with structural analogy with thalidomide].
Vidal M; Gasse C; Garbay C; Galons H
Ann Pharm Fr; 2005 Jan; 63(1):85-9. PubMed ID: 15803105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
